Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
08:45am, Friday, 01'st May 2026
Moderna (MRNA) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $2.52 per share a year ago.
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
07:53am, Friday, 01'st May 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected...
Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
07:46am, Friday, 01'st May 2026
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
Breakfast News: Atlassian Pops 25% On AI Power
07:30am, Friday, 01'st May 2026
Atlassian posts big Q1 gains, Reddit and Twilio beat expectations, and more
Moderna Reports Higher Revenue but Posts a Loss
06:37am, Friday, 01'st May 2026
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
06:32am, Friday, 01'st May 2026
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets.
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
06:30am, Friday, 01'st May 2026
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
07:21am, Thursday, 30'th Apr 2026
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund lau
This iShares ETF Beats Its Mid-Cap Rival on Price -- but Not on Stability
12:07pm, Wednesday, 29'th Apr 2026
Expense ratios, dividend yields, and portfolio composition reveal key differences between these two value-focused iShares funds.
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
11:05am, Wednesday, 29'th Apr 2026
I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise acr
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth
11:05am, Monday, 27'th Apr 2026
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN?
09:30am, Monday, 27'th Apr 2026
From fees to fund size, subtle differences between ISCV and IWN may impact your approach to small-cap value investing.
CureVac sues Moderna for patent infringement over COVID-19 vaccines
04:52pm, Friday, 24'th Apr 2026
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA (mRNA) techn
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Friday, 24'th Apr 2026
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
06:51pm, Wednesday, 22'nd Apr 2026
In the most recent trading session, Moderna (MRNA) closed at $55.6, indicating a +2.53% shift from the previous trading day.
